Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in Combination With Dd, Rd, or DRd in t(11;14) Multiple Myeloma
NCT06042725Phase 1Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax in multiple myeloma (MM) (3 arms), sponsored by Mayo Clinic. Primary endpoint: Dose-limiting toxicity at 28 days. Started Apr 2024; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06042725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06042725.